fda crackdown on compounded semaglutide Attorneys general urge to crack down counterfeit obesity drugs The FDA is proposing the

doi: 10.1111/j.1476-5381.2010.00647.x 144 CaselliGBonazziALanzaMFerrariFMaggioniDFerioliCet al

A 2025 retrospective cohort study of 210 T2DM patients on oral semaglutide for 18 months found no significant association between rs6923761 or rs761387 genotypes and changes in HbA1c or BMI in that relatively well-controlled population (Candido et al., 2025) suggesting that receptor-level genotype effects may be detectable primarily in subpopulations with higher pharmacological demand or larger baseline disease severity, rather than as universal predictors

Both public and private payers use cost containment policies to control the amount and mix of drugs included under the prescription drug benefit, which may be administered by a pharmacy benefit manager, or PBM

While costs for the medication may be expensive, they're also changing the spending habits of people who use them, and with more and more adoption, are likely to shift American consumer spending in new ways